Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
27 Junho 2024 - 5:05PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
today announced that it will report its second quarter 2024
financial and operating results on Thursday, August 1, 2024, before
the U.S. financial markets open. The Company will host a conference
call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the
’Investors and Media’ page of Regeneron’s website at
https://investor.regeneron.com. To participate via telephone,
please register in advance at this link. Upon registration, all
telephone participants will receive a confirmation email detailing
how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access
the call. A replay and transcript of the conference call and
webcast will be archived on the Company’s website for at least 30
days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company
that invents, develops and commercializes
life-transforming medicines for people with serious diseases.
Founded and led by physician-scientists, our unique ability
to repeatedly and consistently translate science into
medicine has led to numerous approved treatments and product
candidates in development, most of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, neurological
diseases, hematologic conditions, infectious diseases, and
rare diseases.
Regeneron pushes the boundaries of scientific
discovery and accelerates drug development using our proprietary
technologies, such as VelociSuite®, which produces optimized fully
human antibodies and new classes of bispecific antibodies. We are
shaping the next frontier of medicine with data-powered insights
from the Regeneron Genetics Center® and pioneering genetic medicine
platforms, enabling us to identify innovative targets and
complementary approaches to potentially treat or cure diseases.
For more information, please visit
www.Regeneron.com or follow Regeneron on LinkedIn, Instagram,
Facebook or X.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com
Corporate Communications Christina Chan
914.847.8827 christina.chan@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024